Effect of chronic treatment with perazine on lipopolysaccharide-induced interleukin-1 beta levels in the rat brain.
In the present study, we sought to determine whether chronic treatment with perazine alters lipopolysaccharide (LPS)-induced interleukin-1 beta (IL-1 beta) levels in the following rat brain regions: the hypothalamus, frontal cortex, striatum and hippocampus. Male Wistar rats were administered perazine dimaleate (15 or 30 mg/kg/day) in drinking water for 21 days. On day 22, LPS was injected i.p. (125 microg/kg) 2 h before decapitation. Concentrations of perazine and its metabolites in plasma and brain was assessed by HPLC. The levels of IL-1 beta were determined using ELISA. Treatment with perazine (30 mg/kg/day) reduced LPS-stimulated IL-1 beta levels in the hypothalamus, and a tendency to its decrease in the striatum and frontal cortex was observed. This in vivo study suggests for the first time that long-term oral administration of perazine modulates reactivity of cells producing IL-1 beta.
Obuchowicz
Ewa
E
Department of Clinical Pharmacology, Silesian University School of Medicine, Medykow 18 Street, 40-752, Katowice, Poland. eobuchowicz@slam.katowice.pl
Marcinowska
Agnieszka
A
Drzyzga
Lukasz
L
Wójcikowski
Jacek
J
Daniel
Władysława A
WA
Herman
Zbigniew S
ZS
D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology*; D001921:Brain / Q000187:drug effects* / Q000276:immunology; D004305:Dose-Response Relationship, Drug; D053583:Interleukin-1beta / Q000032:analysis* / Q000096:biosynthesis; D008070:Lipopolysaccharides / Q000494:pharmacology*; D008297:Male; D010464:Perazine / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar
D014150:Antipsychotic Agents; D053583:Interleukin-1beta; D008070:Lipopolysaccharides; D010464:Perazine